S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Benchmark Raises Amedisys (NASDAQ:AMED) Price Target to $325.00

Last updated on Tuesday, February 23, 2021 | 2021 MarketBeat

Amedisys (NASDAQ:AMED) had its price target increased by Benchmark from $275.00 to $325.00 in a research note issued to investors on Tuesday, The Fly reports. The firm currently has a "buy" rating on the health services provider's stock. Benchmark's price objective indicates a potential upside of 14.20% from the stock's current price.

Other analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft lifted their target price on Amedisys from $275.00 to $340.00 and gave the stock a "buy" rating in a research report on Monday, February 8th. They noted that the move was a valuation call. Barclays boosted their target price on Amedisys from $290.00 to $298.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 3rd. Truist lifted their price target on Amedisys from $280.00 to $325.00 in a research note on Tuesday, January 5th. Finally, Credit Suisse Group upped their price objective on shares of Amedisys from $246.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, October 30th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Amedisys has a consensus rating of "Buy" and an average target price of $268.64.

NASDAQ:AMED opened at $284.60 on Tuesday. The business's 50-day moving average is $299.05 and its two-hundred day moving average is $261.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 0.94 and a quick ratio of 0.94. Amedisys has a 12 month low of $132.95 and a 12 month high of $325.12. The firm has a market capitalization of $9.34 billion, a PE ratio of 57.03, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77.

In other news, CFO Scott G. Ginn sold 975 shares of the firm's stock in a transaction dated Monday, November 30th. The stock was sold at an average price of $241.62, for a total value of $235,579.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Denise M. Bohnert sold 454 shares of the firm's stock in a transaction dated Monday, January 25th. The shares were sold at an average price of $314.41, for a total value of $142,742.14. Following the completion of the sale, the insider now directly owns 7,925 shares in the company, valued at $2,491,699.25. The disclosure for this sale can be found here. Insiders have sold 3,680 shares of company stock worth $1,020,682 over the last three months. Company insiders own 2.80% of the company's stock.

Several large investors have recently modified their holdings of AMED. Parkside Financial Bank & Trust increased its position in Amedisys by 6.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 627 shares of the health services provider's stock valued at $184,000 after acquiring an additional 37 shares in the last quarter. Sabal Trust CO grew its position in shares of Amedisys by 0.6% during the 4th quarter. Sabal Trust CO now owns 6,038 shares of the health services provider's stock worth $1,771,000 after buying an additional 38 shares during the period. Synovus Financial Corp grew its position in shares of Amedisys by 1.2% during the 4th quarter. Synovus Financial Corp now owns 3,363 shares of the health services provider's stock worth $989,000 after buying an additional 39 shares during the period. CAPROCK Group Inc. grew its position in shares of Amedisys by 5.0% during the 4th quarter. CAPROCK Group Inc. now owns 945 shares of the health services provider's stock worth $277,000 after buying an additional 45 shares during the period. Finally, Shilanski & Associates Inc. grew its position in shares of Amedisys by 0.9% during the 4th quarter. Shilanski & Associates Inc. now owns 5,041 shares of the health services provider's stock worth $1,479,000 after buying an additional 46 shares during the period. 85.87% of the stock is currently owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Article: Quantitative Easing

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Penny Stocks That Don’t Care About Robinhood

By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.

However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.

One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.

And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.

But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.

And that’s why you should be looking at them now.

View the "7 Penny Stocks That Don’t Care About Robinhood".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.